Replies to post #43269 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

BOA Rachel raised ARIA's Price Target to $3? That's too high. She should have decreased PT to 0 or -3 now that she doubts Ariad can servive.

No wonder the brightest analyst evaluates lifesaving lung drug AP26113 as ZERO value.

Well said. I thought it was a strange upgrade which hedged it as upgrade but not quite and won't make it...Mötley I think had two articles contradicting each other also...This looks like face saving comments rather than deep analysis of fundamentals....
I would not be surprised if both of them covered their short positions last week in the shakedown to minimize their losses.

For a long term holder like me, this is like watching bowl games from my couch?? Interesting but does not affect my investment strategy..Only facts, fundamentals and results will

If only we all could get paid top dollar for "making it up as we go along"...

In general, I have very little faith in BoA on both the banking and the investment sides based on their performance over the past 5 years.

I won't ridicule Rachel, but she is derfinately not making a good impression with her performance vis a vis ARIA.